Pacira Board Urges Tender as $36.50/Share Viatris Offer Opens, Expires Nov 16
PCRX sits 93% above its 52-week low of $18.8.
Summary
Pacira's board unanimously recommends stockholders tender into Viatris' $36.50-per-share all-cash offer, which opened October 30 and expires November 16, 2026, after the HSR waiting period expired October 29.
Key Events · M&A and Partnerships · PCRX
-
Viatris Tender Offer Opens at $36.50
Viatris' subsidiary is offering $36.50 per share in cash for all Pacira shares; the offer expires at 11:59 p.m. Eastern Time on November 16, 2026, subject to extension.
-
Board Unanimously Recommends Tender
The board determined the merger is fair and in the best interest of stockholders and recommends tendering; Goldman Sachs' October 8, 2026 opinion calls $36.50 fair from a financial point of view.
-
Antitrust Waiting Period Cleared
HSR Premerger Notification forms were filed October 14, 2026, and the waiting period expired at 11:59 p.m. Eastern Time on October 29, 2026, with no voluntary timing agreement.
-
CEO Change-of-Control Package $30.1M
Frank D. Lee's total golden parachute compensation is estimated at $30,132,739, including $24,301,651 of equity; all five named executive officers are disclosed.
Analysis · PCRX · Life Sciences
The Viatris tender offer at $36.50 per share in cash is now formally open, and Pacira's board unanimously recommends that stockholders tender. This is no longer just an announced deal: the HSR antitrust waiting period expired October 29, 2026, and the offer runs to November 16, 2026. The filing also puts hard numbers on insider payouts — CEO Frank D. Lee's change-of-control package totals $30,132,739 — and confirms a $62.0 million termination fee if the board switches to a superior offer. For holders, the practical question is whether to tender into a 45% premium to the $25.20 pre-announcement close or hold for appraisal; with the stock already trading near the $36.50 offer, the remaining return is essentially the deal-completion spread.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, PCRX was trading at $36.35 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.5B. The 52-week trading range was $18.80 to $36.67. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.